PRESS RELEASE published on 07/08/2024 at 23:15, 2 years 2 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 2 years 3 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 2 years 3 months ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 2 years 3 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 2 years 3 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
BRIEF published on 06/19/2024 at 13:05, 2 years 3 months ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
PRESS RELEASE published on 06/19/2024 at 13:00, 2 years 3 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 2 years 3 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 2 years 3 months ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 2 years 3 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 10/01/2026 at 08:02, 2 hours 22 minutes ago Southern Energy Announces Results of Annual Meeting and Board Changes
Published on 10/01/2026 at 01:21, 9 hours 3 minutes ago Revival Gold Announces Filing of Final Base Shelf Prospectus
Published on 10/01/2026 at 01:00, 9 hours 24 minutes ago Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project
Published on 09/30/2026 at 23:30, 10 hours 54 minutes ago Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 13 hours 49 minutes ago Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 10/01/2026 at 10:15, 9 minutes ago OLB Completes Previously Announced Management Board Appointments
Published on 10/01/2026 at 10:12, 11 minutes ago DN Group AG strengthens senior management with sustainability expert Antje Biber
Published on 10/01/2026 at 10:05, 19 minutes ago Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
Published on 10/01/2026 at 10:00, 24 minutes ago iOmx Therapeutics Appoints Rüdiger Wolff as Chief Financial Officer
Published on 10/01/2026 at 09:54, 30 minutes ago Septembre 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 10/01/2026 at 08:30, 1 hour 54 minutes ago Eurazeo opens an office in Abu Dhabi, reinforcing its commitment to the Middle East
Published on 10/01/2026 at 08:30, 1 hour 54 minutes ago Cegedim Business Services dévoile Hospi-DM, sa nouvelle offre SaaS de traçabilité des dispositifs médicaux, lors des 36èmes Journées Euro-Pharmat
Published on 10/01/2026 at 08:30, 1 hour 54 minutes ago Eurazeo ouvre un bureau à Abu Dhabi et renforce son engagement au Moyen-Orient
Published on 10/01/2026 at 08:00, 2 hours 24 minutes ago CNP Assurances and Embracon complete their combination to create a leading consórcio player in Brazil
